Clinical research
Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
이 임상시험이 검증하는 내용
A trial of a base-editing treatment for sickle cell disease, which installs a change that keeps fetal haemoglobin switched on. Dosing has finished in all the adults and adolescents enrolled, and the company has said it may apply for approval as early as the end of 2026.
A Phase 1/2 study of ristoglogene autogetemcel (risto-cel, formerly BEAM-101), an autologous base-edited CD34+ cell therapy inducing fetal haemoglobin, in patients with sickle cell disease and severe vaso-occlusive crises. Dosing is complete in all adult and adolescent participants, with updated data expected by the end of 2026.
Sources
- Beam Therapeutics · 2026
Beam Therapeutics second quarter 2026 results ↗
임상시험 결과가 의미하는 것과 의미하지 않는 것
초기 임상 결과는 소수의 참가자와 짧은 추적 관찰 기간에서 얻은 것입니다. 참가자 수와 시간이 늘어나면 결과가 달라질 수 있으며, 모집 중·진행 중·완료된 임상시험이라도 치료 효과가 입증된 것은 아닙니다. 등록 기준은 엄격하며, 참여 자격은 임상시험 기관이 결정하고 웹사이트가 결정하지 않습니다.